Zonra applies a proprietary feasibility framework to rare and genetic disease programmes, giving sponsors the intelligence to act on site strategy and patient identification before any spend is committed.
Every programme runs through the same four-layer framework. The output is a scored risk profile with site-level recommendations, ready to act on.
Diagnosed and undiagnosed population estimates, genotype stratification, geographic clustering, and patient registry gap analysis. The model locates where patients are before site selection begins.
Gene therapy infrastructure readiness, long-term follow-up capacity, vector handling requirements, investigator experience scoring, and competing trial load. Sites are ranked globally.
Active and planned trials competing for the same patient pool. Sponsor profiles, projected enrollment timelines, and patient access pressure modeled across each geography.
A composite score synthesising all four layers, with site-level and region-level mitigation recommendations. A decision-ready intelligence document, not a research summary.
Disease area, development stage, geography, and known constraints. The framework is calibrated to your programme, not applied as a template.
All four layers run across your programme, drawing on epidemiological registries, published literature, proprietary site data, and competitive intelligence sources.
A structured intelligence document with your Enrollment Risk Index, a scored site list, and mitigation recommendations. Followed by a live readout with your team.
Three to four weeks from scope call to delivery, within pre-IND and pre-CRO engagement windows.
The intelligence produced in each engagement contributes to the Zonra site and patient database, improving model accuracy across future programmes.
Begin an engagementThe constraint is not patient absence. It is the absence of infrastructure to locate and qualify those patients within a trial framework. No site readiness data. No registry coverage built for rare disease in Africa.
Zonra is building that infrastructure, starting with Nigeria and expanding across the continent. Each engagement deepens the model toward that goal.
Discuss Africa strategyGene therapy and rare disease developers approaching pivotal studies. The Zonra model validates enrollment feasibility before the programme is locked in.
Rare disease programmes moving from academic discovery into clinical development. Zonra provides the enrollment evidence base that IND submissions require.
Global programmes evaluating African sites for the first time. Zonra maps qualified sites, patient populations, and regulatory pathways from the outset.
Tell us about your programme. Zonra will scope the right engagement for your disease area, geography, and development stage.